Molecular diagnostics for field use during pandemic situations must be developed quickly; they should be highly sensitive, specific, inexpensive, and rapidly deployable; and they should provide timely diagnostic capabilities in low-resource areas. Additionally, they need to be easy to use and interpret without technical expertise. Production should be highly scalable for implementation on a global scale…a supportive regulatory environment is crucial to developing and using these in vitro paper-based diagnostics.
